An RVC Biofund portfolio company will create a Research Center on the Sirius site
ExoAtlet, an RVC Biofund portfolio company, has launched pilot projects for home exo-rehabilitation. The company's products — the ExoAtlet I and ExoAtlet Bambini exoskeletons — have attracted their first private customers, who have begun exercises right at home.
ExoAtlet, an RVC Biofund portfolio company, successfully completed trials and received a registration certificate for the ExoAtlet II exoskeleton, which was previously certified by the European Union. The training apparatus is the second exoskeleton in the company's lineup to achieve medical certification in the Russian market.
The RBV Capital Fund, created with the participation of capital RVC  and R-Pharm, invested 105 million rubles in PanDx, which is developing a multifunctional catheter “Izikat” for the treatment of severe diseases of the gastrointestinal tract.
Intellojik has attracted 160 million roubles of investment in round B in order to further develop the artificial intelligence platform for medical research analysis Botkin.AI.
The volume of the venture transactions market in Russia in the first half of 2020 decreased by 9% to 240 million dollars, compared to 262.8 million dollars in the first half of 2019. At the same time, the number of transactions decreased by almost one and a half times — from 130 to 78 transactions. About 90% of the total investment during this period was in the expansion phase.
The RVC Biofund closed the deal to sell its 17.79% stake in the Genetico portfolio company Center for Genetics and Reproductive Medicine (hereinafter — Genetico).
According to the results of the assessment of the investment portfolio of RVC as of the end of the third quarter of 2020, the return on capital indicator (TVPI) exceeded the figure of one.

1 2 3 4 5 ... 12 Next

Search by name:

Search by date:

Select date in calendar
Select date in calendar